Merck, Inc.
🇵🇭Philippines
A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Biological: RobatumumabDrug: IrinotecanBiological: CetuximabDrug: CapecitabineDrug: FOLFOXDrug: CAPEOX/XELOXDrug: FOLFIRI
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 67
- Registration Number
- NCT00551213
A Study to Examine the Efficacy and Safety of Posaconazole When Introduced Early in the Treatment of Refractory Fungal Infections (P05090 AM2)
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00550732
Vicriviroc in HIV(R5/X4)-Treatment Experienced Subjects (Study P05057AM5)(COMPLETED)
Phase 2
Completed
- Conditions
- HIV InfectionsAcquired Immunodeficiency Syndrome
- Interventions
- Drug: PlaceboDrug: Vicriviroc
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 111
- Registration Number
- NCT00551330
Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875)
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 218
- Registration Number
- NCT00551018
Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)
Phase 2
Completed
- Conditions
- Breast Neoplasm
- Interventions
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 181
- Registration Number
- NCT00550771
ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)
Phase 4
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: Zoster Vaccine, Live
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2017-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11999
- Registration Number
- NCT00550745
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
Phase 2
Completed
- Conditions
- Genital WartsHuman Papillomavirus InfectionVaginal CancerCervical CancerVulvar Cancer
- Interventions
- Biological: V504
- First Posted Date
- 2007-10-30
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 620
- Registration Number
- NCT00551187
A Study of Gastric Delay in Migraine Patients (3207-003)
Phase 1
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: MK3207
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2014-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 22
- Registration Number
- NCT00548353
Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055)
Phase 3
Completed
- Conditions
- Fungal Infection
- First Posted Date
- 2007-10-23
- Last Posted Date
- 2015-12-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 131
- Registration Number
- NCT00548080
Dyslipidemia in Type 2 Diabetes (0767-034)
Phase 3
Terminated
- Conditions
- Diabetes Mellitus, Type IIDyslipidemia
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 111
- Registration Number
- NCT00547274
© Copyright 2025. All Rights Reserved by MedPath